Autologous peripheral blood-derived CD34+ cells
Identification
- Generic Name
- Autologous peripheral blood-derived CD34+ cells
- DrugBank Accession Number
- DB16367
- Background
Autologous peripheral blood-derived CD34+ cells, or CLBS119 (a proprietary version being developed by Caladrius Biosciences, Inc.), are hematopoietic stem cells.1 It is also a cell therapy being investigated by Caladrius Biosciences in the clinical trial NCT04522817 (CLBS119 for Repair of COVID-19 Induced Pulmonary Damage).
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Cell transplant therapies
Other cell transplant therapies - Synonyms
- CD34+ Cells
- CLBS119
- External IDs
- Autologous peripheral blood-derived CD34+ cells
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Autologous peripheral blood-derived CD34+ cells have potential tissue repair ability in part due to its anti-inflammatory function which were demonstrated in pre-clinical models, including one of lung inflammation.1 Due to the pre-programmed tissue repair effects mediated by anti-inflammatory and pro-angiogenic functions of these cells, this cell therapy is currently being investigated against COVID-19-induced lung damage in recovered adult patients that still are experiencing hypoxia and require supplemental oxygen.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Strimvells 5000000 cells/ml Intravenous Fondazione Telethon Ets 2020-12-20 Not applicable EU
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Caladrius Biosciences: CLBS119 [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment (Advanced) Coronary Heart Disease / Chronic Myocardial Ischemia / Refractory Angina Pectoris 1 3 Terminated Supportive Care Graft-versus-host Disease (GVHD) / Leukemias / Lymphoma 1 2 Completed Treatment Atherosclerosis Obliterans / Buerger's Disease / Critical Limb Ischemia (CLI) / Thrombo Angiitis Obliterans 1 2 Completed Treatment Leukemias / Lymphoma / Myelodysplastic Syndrome 1 2 Completed Treatment Multiple Myeloma (MM) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 18, 2020 16:55 / Updated at March 03, 2021 21:58